Infosys (INFY) Q2 2026 Earnings Transcript

Infosys reported Q2 constant-currency revenue growth of 2.2% sequentially and 2.9% year over year, with operating margin at 21% and large deals totaling $3.1 billion, 67% of which were new or net new. Management raised full-year revenue growth guidance to 2%-3% while keeping margin guidance at 20%-22%, and announced a $1.6 billion U.K. NHS mega deal plus an INR 18,000 crore buyback plan pending approval. The call emphasized strong AI-related demand, continued hiring of 8,000 net employees in the quarter, and ongoing uncertainty around the macro environment and H-1B policy.

Analysis

INFY is not being rewarded for a clean quarter so much as for evidence that its operating model is now more resilient to a weak demand tape than the market expected. The subtle shift is that management is leaning harder into localization, nearshore delivery, and campus hiring, which lowers its exposure to U.S. visa friction and makes delivery continuity less cyclical than headline commentary implies. That should support relative multiple stability versus peers with more offshore-heavy delivery and less geographic diversification.

The bigger second-order effect is on deal quality, not just deal volume. A pipeline dominated by cost takeout, automation, and AI-led transformation favors vendors with broad horizontal capability and implementation scale, which tends to widen the gap versus niche players that can demo AI but cannot industrialize it across enterprise workflows. The NHS win also matters because public-sector transformation tends to be stickier, lower-churn, and reference-generating across Europe, potentially improving medium-term visibility even if near-term growth remains subdued.

The contrarian risk is that the market may be overestimating the durability of margin expansion. A large part of the quarterly uplift came from pricing and mix, while subcontracting and utilization are still moving against them; if furloughs, weak working days, or delayed client decision-making hit into the seasonally softer second half, margins could mean-revert faster than consensus expects. AI is still an adoption story, not yet a monetization story, so any attempt to re-rate INFY on AI revenue disclosure before material contribution appears likely to disappoint.

Net/net, this reads as a quality defensive in Indian IT rather than a growth re-acceleration story. The cleanest setup is relative outperformance if macro deteriorates modestly, but upside should be capped unless management can prove that AI and large deals are converting into sustained revenue acceleration rather than merely preserving share and margin.

Key Decisions for Investors

• Long INFY vs. short a more U.S.-visa-exposed IT services peer for the next 2-3 quarters; thesis is lower delivery disruption risk and better localization optionality. Best entry on any post-call pullback, targeting 8-12% relative outperformance if macro stays choppy.
• Buy INFY on dips as a defensive cash-return compounder, not a growth name; use a 6-9 month horizon and underwrite ~2%-3% CC growth with 20%-22% margins. Risk/reward favors owning into buyback approval if the stock de-rates on underwhelming AI monetization.
• Avoid paying up for AI narrative beta in INFY until management quantifies contribution; short-term upside from an AI re-rate looks limited. If you want AI leverage, express it elsewhere rather than via this name.
• Consider a pair: long INFY / short a higher-expectation global IT services stock that needs accelerating bookings to justify its multiple. This works best if second-half demand stays uncertain and capital flows favor defensives.
• For event traders, sell covered calls against existing INFY longs into any bounce after buyback headlines; the stock has more visible downside protection than upside catalyst density over the next 30-45 days.